IntrinsicIntrinsic
← All summaries

Jazz Pharmaceuticals plc

JAZZ
Financials & Chart →

Business Summary

Jazz Pharmaceuticals plc is a global biopharmaceutical company dedicated to developing life-changing medicines for people with rare disease, often with limited or no therapeutic options. The company has a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. The company's strategy for growth is rooted in executing commercial launches and ongoing commercialization initiatives, advancing robust R&D programs and delivering impactful clinical results, effectively deploying capital to strengthen the prospects of achieving its short- and long-term goals through strategic corporate development, and delivering strong financial performance. The company focuses on rare diseases, which often have high unmet needs and small patient populations, resulting in efficient, concentrated call points.

The biopharmaceutical industry is highly competitive. Jazz Pharmaceuticals' products compete with currently existing therapies, product candidates currently under development by itself and others, and future product candidates, including new chemical entities that may be safer, more effective or more convenient. Competitors include large global pharmaceutical companies and small research-based companies and institutions. Specific named competitors include Alkermes plc (through its acquisition of Avadel), Axsome Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Merck & Co., Inc., Eisai Co., Ltd., Centessa Pharmaceuticals plc, Harmony Biosciences, Amgen Inc., and various generic drug manufacturers such as Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Lupin Inc., Teva Pharmaceuticals, Inc., and Granules India Limited. The company's competitive advantages include its focus on rare diseases, its efficient commercialization model, and its portfolio of products with regulatory exclusivities such as Orphan Drug Exclusivity.

The company generates revenue primarily through net product sales of its commercialized medicines and through royalties and contract revenues. Product sales are recognized when control has transferred to the customer, which occurs at a point in time, typically on delivery. The company's revenue mix includes both recurring income from established products and income from newly launched products. Primary customer segments include specialty pharmacies, specialty distributors, and hospital customers. The company leverages an efficient, scalable operating model and integrated capabilities across its global infrastructure.

The company's lead marketed products include Xywav, a low-sodium oxybate therapy for narcolepsy and idiopathic hypersomnia (IH), with net product sales of $1,656,986 thousand in 2025, representing 41% of total net product sales. Xyrem, a high-sodium oxybate, had net product sales of $146,034 thousand in 2025, representing 4% of total net product sales. Epidiolex/Epidyolex, a cannabidiol treatment for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), and tuberous sclerosis complex (TSC), had net product sales of $1,059,197 thousand in 2025, representing 26% of total net product sales. In the rare oncology segment, Zepzelca (lurbinectedin) for small cell lung cancer (SCLC) had net product sales of $307,309 thousand in 2025, representing 8% of total net product sales. Rylaze/Enrylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) had net product sales of $402,920 thousand in 2025, representing 10% of total net product sales. Defitelio/defibrotide for veno-occlusive disease (VOD) had net product sales of $199,392 thousand in 2025. Vyxeos (daunorubicin and cytarabine) for acute myeloid leukemia (AML) had net product sales of $146,709 thousand in 2025. Modeyso (dordaviprone) for diffuse midline glioma had net product sales of $48,043 thousand in 2025, following its launch in August 2025. Ziihera (zanidatamab-hrii) for HER2-positive biliary tract cancer (BTC) had net product sales of $24,810 thousand in 2025, following its launch in December 2024.

The company's neuroscience segment also includes Sativex (nabiximols), which was divested on October 31, 2025, and had net product sales of $16,277 thousand in 2025. Total Neuroscience product sales were $2,878,494 thousand in 2025. Total Oncology product sales were $1,129,183 thousand in 2025. Other product sales were $14,172 thousand in 2025. The company also earns high-sodium oxybate authorized generic (AG) royalty revenue, which was $211,725 thousand in 2025, and other royalty and contract revenues of $34,012 thousand in 2025.

In 2025, the company completed the acquisition of Chimerix, Inc. for total cash consideration of $944.2 million , adding Modeyso to its rare oncology portfolio. Modeyso received FDA accelerated approval in August 2025. The company also entered into a global license agreement with Saniona for JZP053, making an upfront payment of $42.5 million . The company settled the Xyrem Antitrust Litigation, incurring settlement expenses of $233.5 million , and settled the Avadel Litigation, incurring a settlement expense of $90.0 million . The company repurchased 1.1 million of its ordinary shares for $125.0 million under its New Repurchase Program. The company made a voluntary repayment of $750.0 million on its Tranche B-2 Dollar Term Loans in January 2025. In connection with the FDA approval of Modeyso, the company received a rare pediatric disease priority review voucher, which it sold in January 2026 for total cash consideration of $200.0 million , of which 50% is attributable to the company.

Total revenues for 2025 were $4,267,586 thousand , a 5% increase from $4,068,950 thousand in 2024. Net product sales were $4,021,849 thousand in 2025, compared to $3,821,164 thousand in 2024. The company reported a net loss of $356,148 thousand for 2025, compared to net income of $560,120 thousand in 2024. The net loss was primarily driven by acquired in-process research and development expenses of $947,862 thousand related to the Chimerix Acquisition and the Saniona license, and litigation settlement expenses. Net cash provided by operating activities was $1,355,773 thousand in 2025. As of December 31, 2025, the company had cash, cash equivalents and investments of $2.4 billion and total indebtedness of approximately $5.4 billion .

Business Outlook

The company's current 2026 operating plan assumes that Xywav will remain the #1 branded oxybate treatment for narcolepsy, the position it held based on revenue in the fourth quarter of 2025. The company expects total revenues in 2026 to increase compared to 2025, driven by continued growth in its rare oncology and epilepsy products including Modeyso, Ziihera and Epidiolex/Epidyolex, offset by a reduction in oxybate revenues due to decreased high-sodium AG royalties and Xyrem revenues following the launch of multiple generic high-sodium products. The company expects its cost of product sales in 2026 to be in line with 2025. The company expects selling, general and administrative expenses in 2026 to decrease compared to 2025, primarily due to the impact of litigation settlement expenses incurred in 2025. For 2026, the company expects that its R&D expenses will increase compared to 2025, primarily driven by an increase in clinical studies and outside service costs relating to zanidatamab, dordaviprone, and preclinical and early clinical programs.

A key growth vector is the continued expansion of the company's rare oncology portfolio. This includes the ongoing clinical development of zanidatamab, with positive top-line results from the pivotal Phase 3 HERIZON-GEA-01 trial in first-line HER2-positive gastroesophageal adenocarcinoma (GEA), showing a statistically significant and clinically meaningful overall survival benefit. The company is also pursuing a Phase 3 confirmatory trial for zanidatamab in first-line HER2-positive BTC (HERIZON-BTC-302) and a Phase 3 trial in previously treated HER2-positive breast cancer (EmpowHER-BC-303). Another growth vector is the expansion of Modeyso, which received FDA accelerated approval in August 2025 for diffuse midline glioma, with a confirmatory Phase 3 ACTION trial ongoing in the first-line setting. The company is also advancing its early-stage pipeline, including JZP815 (a pan-RAF inhibitor), JZP898 (a conditionally-activated IFNα molecule), and JZP053 (a Kv7.2/Kv7.3 potassium channel activator for epilepsy).

The company expects its cost of product sales in 2026 to be in line with 2025. The company expects selling, general and administrative expenses in 2026 to decrease compared to 2025, primarily due to the impact of litigation settlement expenses incurred in 2025. For 2026, the company expects that its R&D expenses will increase compared to 2025, primarily driven by an increase in clinical studies and outside service costs relating to zanidatamab, for both ongoing and new studies, dordaviprone, due to the inclusion of a full year's expenses, and preclinical and early clinical programs.

The company has a manufacturing and development facility in Athlone, Ireland where it manufactures Xywav and Xyrem, a manufacturing and development facility in Kent Science Park, U.K. where it produces Epidiolex/Epidyolex, and a manufacturing plant in Villa Guardia, Italy where it produces defibrotide drug substance. The company relies on third-party suppliers for most of its other products. The company has increased inventory levels of its products in the U.S. in anticipation of potential increased tariffs. The company employs approximately 2,890 people worldwide as of December 31, 2025, with more than 740 employees supporting R&D activities.

The company expects to continue to generate positive cash flow from operations which it expects will enable it to operate its business and de-lever its balance sheet over time. The company plans to commit substantial resources to product acquisition and in-licensing, product development, clinical trials of product candidates and expansion of its commercial, development, manufacturing and other operations. The company expects to continue to opportunistically seek access to additional capital to license or acquire additional products, product candidates or companies to expand its operations, to restructure or refinance its debt and/or for general corporate purposes. As of December 31, 2025, the remaining amount authorized for repurchases under the New Repurchase Program was $225.0 million .

The company faces significant headwinds from competition in its oxybate franchise, including from Alkermes' Lumryz and from authorized generic and generic versions of high-sodium oxybate. The company expects that the approval and launch of AG products or other generic versions of Xyrem or Xywav and the approval and launch of any other sodium oxybate product will continue to have a negative impact on sales of Xywav and Xyrem. The company also faces headwinds from global trade issues and tariffs, which could increase costs and reduce competitiveness. The company anticipates that its margins could be adversely affected by tariffs beginning as early as fiscal 2026. The company is also subject to increasing pricing pressure and restrictions on reimbursement imposed by payors, and to healthcare cost containment and drug pricing scrutiny by regulatory agencies in the U.S. and internationally.

The company faces structural headwinds from the potential for increased tariffs on pharmaceutical products imported into the U.S., which could increase its manufacturing costs and supply chain complexity. The company also faces regulatory and macro factors, including the impact of the Inflation Reduction Act of 2022 (IRA), which requires the HHS Secretary to negotiate the price of certain high Medicare spend drugs and penalizes manufacturers for price increases above inflation. The company is also subject to the OECD's Pillar Two global minimum tax rules, which could adversely affect its effective tax rate. The company's ability to use its net operating losses (NOLs) to offset future taxable income is subject to limitations under applicable law.

Risk Factors

The company's inability to maintain revenues from its oxybate franchise would have a material adverse effect on its business, as the company's current 2026 operating plan assumes Xywav will remain the #1 branded oxybate treatment for narcolepsy. The introduction of new products in the U.S. market that compete with, or otherwise disrupt the market for, the company's oxybate products has adversely affected and may continue to adversely affect sales. The company faces substantial competition from other companies, including companies with larger sales organizations and more experience working with large and diverse product portfolios, and competition from generic drugs. The company has incurred substantial debt, with total indebtedness of approximately $5.4 billion as of December 31, 2025, which could impair its flexibility and access to capital. The company may not realize the anticipated benefits from its acquisition of Chimerix, for which it paid total cash consideration of $944.2 million .

Management Priorities

Management's message emphasizes the company's purpose to innovate to transform the lives of patients and its focus on rare diseases. Key strategic priorities for the period ahead include strong commercial execution to drive diversified revenue growth, expanding and advancing the pipeline to achieve a valuable portfolio of durable, highly differentiated products, building an efficient and productive development engine, identifying and acquiring novel product candidates and approved therapies, investing in an efficient, scalable operating model, and unlocking further value through indication expansion and entry into global markets. The company's current 2026 operating plan assumes that Xywav will remain the #1 branded oxybate treatment for narcolepsy. The company expects total revenues in 2026 to increase compared to 2025, driven by continued growth in its rare oncology and epilepsy products including Modeyso, Ziihera and Epidiolex/Epidyolex, offset by a reduction in oxybate revenues. The company expects selling, general and administrative expenses in 2026 to decrease compared to 2025, primarily due to the impact of litigation settlement expenses incurred in 2025. The company expects that its R&D expenses in 2026 will increase compared to 2025.

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 7, MD&A — Results of Operations
  2. [2] Item 7, MD&A — Results of Operations
  3. [3] Item 7, MD&A — Results of Operations
  4. [4] Item 7, MD&A — Results of Operations
  5. [5] Item 7, MD&A — Results of Operations
  6. [6] Item 7, MD&A — Results of Operations
  7. [7] Item 7, MD&A — Results of Operations
  8. [8] Item 7, MD&A — Results of Operations
  9. [9] Item 7, MD&A — Results of Operations
  10. [10] Item 7, MD&A — Results of Operations
  11. [11] Item 7, MD&A — Results of Operations
  12. [12] Item 7, MD&A — Results of Operations
  13. [13] Item 7, MD&A — Results of Operations
  14. [14] Item 7, MD&A — Results of Operations
  15. [15] Item 7, MD&A — Results of Operations
  16. [16] Item 7, MD&A — 2025 Highlights and Recent Developments
  17. [17] Item 7, MD&A — 2025 Highlights and Recent Developments
  18. [18] Item 7, MD&A — Results of Operations
  19. [19] Item 7, MD&A — Results of Operations
  20. [20] Item 5, Issuer Purchases of Equity Securities
  21. [21] Item 7, MD&A — Liquidity and Capital Resources
  22. [22] Item 7, MD&A — Liquidity and Capital Resources
  23. [23] Item 1, Business — Our Rare Oncology Products
  24. [24] Item 7, MD&A — Results of Operations
  25. [25] Item 7, MD&A — Results of Operations
  26. [26] Item 7, MD&A — Results of Operations
  27. [27] Item 7, MD&A — Results of Operations
  28. [28] Item 8, Consolidated Statements of Income (Loss)
  29. [29] Item 8, Consolidated Statements of Income (Loss)
  30. [30] Item 7, MD&A — Results of Operations
  31. [31] Item 7, MD&A — Liquidity and Capital Resources
  32. [32] Item 7, MD&A — Liquidity and Capital Resources
  33. [33] Item 1A, Risk Factors — Risks Related to Our Financial Condition and Results
  34. [34] Item 1, Business — High Performance Organization and Human Capital Management
  35. [35] Item 1, Business — High Performance Organization and Human Capital Management
  36. [36] Item 5, Issuer Purchases of Equity Securities
  37. [37] Item 1A, Risk Factors — Risks Related to Our Financial Condition and Results
  38. [38] Item 7, MD&A — 2025 Highlights and Recent Developments
  39. [39] Item 8, Consolidated Statements of Income (Loss)
  40. [40] Item 8, Consolidated Statements of Income (Loss)
  41. [41] Item 8, Consolidated Statements of Income (Loss)
  42. [42] Item 8, Consolidated Statements of Income (Loss)
  43. [43] Item 8, Consolidated Statements of Income (Loss)
  44. [44] Item 8, Consolidated Statements of Income (Loss)
  45. [45] Item 8, Consolidated Statements of Income (Loss)
  46. [46] Item 8, Consolidated Statements of Income (Loss)
  47. [47] Item 8, Consolidated Statements of Income (Loss)
  48. [48] Item 8, Consolidated Statements of Income (Loss)
  49. [49] Item 8, Consolidated Statements of Income (Loss)
  50. [50] Item 8, Consolidated Statements of Income (Loss)
  51. [51] Item 8, Consolidated Statements of Income (Loss)
  52. [52] Item 8, Consolidated Statements of Income (Loss)
  53. [53] Item 8, Consolidated Statements of Income (Loss)
  54. [54] Item 8, Consolidated Statements of Income (Loss)
  55. [55] Item 8, Consolidated Statements of Income (Loss)
  56. [56] Item 8, Consolidated Statements of Income (Loss)
  57. [57] Item 7, MD&A — Results of Operations
  58. [58] Item 7, MD&A — Results of Operations
  59. [59] Item 7, MD&A — Liquidity and Capital Resources
  60. [60] Item 7, MD&A — Liquidity and Capital Resources
  61. [61] Item 7, MD&A — Liquidity and Capital Resources
  62. [62] Item 8, Consolidated Balance Sheets
  63. [63] Item 8, Consolidated Balance Sheets
  64. [64] Item 8, Consolidated Balance Sheets
  65. [65] Item 7, MD&A — Results of Operations
  66. [66] Item 7, MD&A — Results of Operations
  67. [67] Item 7, MD&A — 2025 Highlights and Recent Developments
  68. [68] Item 7, MD&A — Results of Operations
  69. [69] Item 7, MD&A — Results of Operations
  70. [70] Item 7, MD&A — Results of Operations

Analysis on 6/8/2026